Compare Philip Morris International Inc. (PM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Revvity Inc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Philip Morris International Inc. is far larger — about 23.8× Revvity Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| PM | RVTY | |
|---|---|---|
Market Cap | $293.07B | $12.33B |
Sector | Consumer Staples | Technology |
52-Week High | $192.98 | $117.75 |
52-Week Low | $144.33 | $82.26 |
Enterprise Value | $339.57B | $14.82B |
Dividend Yield | 3.13% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $194.30, up 0.82% today, with strong analyst support (68% buy ratings) and a consensus price target of $194. The stock shows bullish technical momentum above key support levels, supported by robust fundamentals including 2025 revenue of $40.65B and net income of $11.35B. Recent news highlights include a $500M impairment charge and updated 2026 guidance, while the IQOS brand gained recognition as a top global brand.
PM offers stable dividend income and growth potential, but faces headwinds from cost pressures, currency volatility, and regulatory risks in tobacco markets. The current valuation at 26.47 P/E appears reasonable given earnings consistency, though investors should monitor margin trends and illicit market impacts in Europe. Near-term price action hinges on Q2 2026 earnings versus the $2.04 EPS estimate.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
